| Serial Number | 79379489 |
| Word Mark | QUAD X |
| Filing Date | Wednesday, April 19, 2023 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, December 3, 2024 |
| Registration Number | 7583012 |
| Registration Date | Tuesday, December 3, 2024 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 1, 2024 |
| Goods and Services | Pharmaceutical preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; biological preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; diagnostic preparations agents, and substances for medical purposes; anti-angiogenesis preparations; anti-cancer preparations; anti-inflammatory preparations; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; diagnostic reagents for medical use; DNA, antibodies and proteins for medical diagnosis purposes; DNA and antibodies and proteins that stimulate cells for medical use; DNA, antibodies and proteins for therapeutic use for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; diagnostic preparations for medical purposes; reagents for medical use |
| Goods and Services | Medical and pharmacological research services; scientific and technological services, namely scientific research, analysis and testing in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; scientific research for medical purposes in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; pharmaceutical research and drug development services; pharmaceutical testing; research and development in the biotechnology field; research and development services in the field of antibodies; biotechnology research services; scientific research in the nature of conducting clinical trials for others; biological research, clinical research and medical research; providing scientific information about the results of clinical trials for pharmaceutical products; research services in the field of diagnostic preparations; scientific laboratory services; custom design and development of biochemical assays; scientific and medical research laboratory services; research and development of new products for others; scientific research and analysis in the field of drug discovery; new product development in the field of pharmaceuticals for others; scientific advisory services, namely, medical advisory services related to pharmaceutical development and testing; scientific research consultancy in the field of cancer research, inflammatory disease research, auto-inflammatory disease research, autoimmune disease research, eye disease and disorder research, and intracellular delivery research of pharmaceuticals and therapeutics; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals; consulting services for others in the field of design, planning, and implementation and project management of scientific research and clinical trials; providing scientific research information; technical advisory services relating to scientific and clinical research; provision of technical and scientific information and consultancy in relation to the aforesaid services |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 29, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 29, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Elasmogen Ltd |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Elasmogen Ltd |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Elasmogen Ltd |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Tuesday, October 3, 2023 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, January 17, 2024 | ASSIGNED TO EXAMINER |
| Thursday, September 28, 2023 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, September 29, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, January 17, 2024 | NON-FINAL ACTION WRITTEN |
| Thursday, January 18, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, February 1, 2024 | REFUSAL PROCESSED BY MPU |
| Thursday, February 1, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Monday, February 19, 2024 | REFUSAL PROCESSED BY IB |
| Monday, July 29, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, July 29, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, July 29, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, August 27, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, September 11, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, October 1, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, October 1, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 3, 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Monday, March 3, 2025 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Thursday, February 27, 2025 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Tuesday, December 3, 2024 | REGISTERED-PRINCIPAL REGISTER |
| Thursday, February 27, 2025 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |